Nektar Therapeutics (NKTR) Misses Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $66.69 +1.51%
EPS Growth %: +26.6%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: +26.6%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.36), $0.03 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $32.77 million versus the consensus estimate of $30.47 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
